Brito Juan P, Davies Louise
aKnowledge and Evaluation Research Unit, Division of Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota bVA Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vermont cGeisel School of Medicine at Dartmouth, The Dartmouth Institute for Health Policy & Clinical Practice, Hanover, New Hampshire, USA.
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):405-8. doi: 10.1097/MED.0000000000000094.
Between 1975 and 2009, the incidence of thyroid cancer has increased from 4.9 to 14.3 cases per 100 000 individuals, with a more pronounced increase in women (from 6.5 to 21.4 cases per 100 000 women). In the USA, in 2013, there are now more cases of thyroid cancer than all leukemias, pancreas and liver cancers combined. This review assesses the current evidence around the hypothesis that thyroid cancer is overdiagnosed: cancers are being detected that were never destined to cause a patient harm.
There is a large reservoir of slow or nonprogressing thyroid cancers; up to one-third of the population may unknowingly harbor a thyroid cancer. At least two activities have contributed to the detection of this reservoir of thyroid cancer: the increasing use of advanced imaging modalities in the recent years (i.e., computed tomography and MRI) and increased rates of thyroid surgery coupled with more aggressive evaluation of excised thyroid glands. Despite the increased incidence of thyroid cancer, mortality has not changed over the last 4 decades. This mismatch between incidence and mortality is most consistent with increased identification of nonlethal disease (overdiagnosis).
Thyroid cancer incidence is increasing, although mortality is stable. The major cause of the increased incidence is detection of subclinical disease - overdiagnosis. Patients are still treated aggressively and are exposed to side-effects of treatment without any certainty of benefit. Strategies to avoid unnecessary intervention and to explicitly involve patients in decision-making should be pursued. Research is needed to help predict which cancers are likely to become problematic.
1975年至2009年间,甲状腺癌的发病率从每10万人4.9例增至14.3例,女性的增幅更为显著(从每10万女性6.5例增至21.4例)。在美国,2013年甲状腺癌的病例数现已超过白血病、胰腺癌和肝癌病例数之和。本综述评估了关于甲状腺癌被过度诊断这一假说的现有证据:即检测出的癌症从未注定会对患者造成伤害。
存在大量生长缓慢或不进展的甲状腺癌;高达三分之一的人群可能在不知情的情况下患有甲状腺癌。至少有两项活动促成了对这类甲状腺癌的检测:近年来先进成像方式(即计算机断层扫描和磁共振成像)的使用增加,以及甲状腺手术率上升,同时对切除的甲状腺进行了更积极的评估。尽管甲状腺癌发病率上升,但过去40年死亡率并未改变。发病率与死亡率之间的这种不匹配最符合对非致命性疾病的更多识别(过度诊断)。
甲状腺癌发病率在上升,尽管死亡率稳定。发病率上升的主要原因是亚临床疾病的检测——过度诊断。患者仍接受积极治疗,并暴露于治疗的副作用之下,却无法确定是否有益。应采取策略避免不必要的干预,并让患者明确参与决策。需要开展研究以帮助预测哪些癌症可能会出现问题。